Abstract
The fusion protein MG7-scFv/SEB has shown anti-tumor activity on gastric cancer in vitro and in vivo. Tumor necrosis factor-alpha (TNF-α) is a cytokine exerting anti-tumor effectiveness in various models and modes of applications. In this study, we explored the combination effects of MG7-scFv/SEB and TNF-α in experimental gastric cancer. Both MG7-scFv/SEB and TNF-α could effectively result in a significant inhibition of tumor growth in our experimental models when administered alone. What’s more, MG7-scFv/SEB synergized with TNF-α in further reducing the growth of gastric tumors in gastric-tumor-bearing rats as compared to mono therapy. Additionally, the survival rate of gastric-tumorbearing rats administrated with combined therapy was significantly higher than that of rats treated with MG7-scFv/SEB or TNF-α. These results indicate that combined therapy with MG7-scFv/SEB and TNF-α is a promising strategy for human cancer therapy.
Keywords: Superantigens, MG7-scFv/SEB, tumor necrosis factor, combination, gastric cancer, fusion protein, cytokine, gastric tumor, combined therapy, cancer therapy
Protein & Peptide Letters
Title:Synergistic Enhancement of Cancer Therapy Using a Combination of Fusion Protein MG7-scFv/SEB and Tumor Necrosis Factor Alpha
Volume: 20 Issue: 4
Author(s): Xiaoming Lu, Chao Cheng, Guobin Wang, Xiaogang Shu, Jingwei Ma and Qiang Tong
Affiliation:
Keywords: Superantigens, MG7-scFv/SEB, tumor necrosis factor, combination, gastric cancer, fusion protein, cytokine, gastric tumor, combined therapy, cancer therapy
Abstract: The fusion protein MG7-scFv/SEB has shown anti-tumor activity on gastric cancer in vitro and in vivo. Tumor necrosis factor-alpha (TNF-α) is a cytokine exerting anti-tumor effectiveness in various models and modes of applications. In this study, we explored the combination effects of MG7-scFv/SEB and TNF-α in experimental gastric cancer. Both MG7-scFv/SEB and TNF-α could effectively result in a significant inhibition of tumor growth in our experimental models when administered alone. What’s more, MG7-scFv/SEB synergized with TNF-α in further reducing the growth of gastric tumors in gastric-tumor-bearing rats as compared to mono therapy. Additionally, the survival rate of gastric-tumorbearing rats administrated with combined therapy was significantly higher than that of rats treated with MG7-scFv/SEB or TNF-α. These results indicate that combined therapy with MG7-scFv/SEB and TNF-α is a promising strategy for human cancer therapy.
Export Options
About this article
Cite this article as:
Lu Xiaoming, Cheng Chao, Wang Guobin, Shu Xiaogang, Ma Jingwei and Tong Qiang, Synergistic Enhancement of Cancer Therapy Using a Combination of Fusion Protein MG7-scFv/SEB and Tumor Necrosis Factor Alpha, Protein & Peptide Letters 2013; 20 (4) . https://dx.doi.org/10.2174/0929866511320040011
DOI https://dx.doi.org/10.2174/0929866511320040011 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Prevention and Therapy in a Preclinical Mouse Model: Impact of FHIT Viruses
Current Gene Therapy Pharmacokinetic Distribution of 67Cu(II)2[3,5-Diisopropyl(Carboxy- 14C)Salicylate]4 Among Murine Tissues
Current Medicinal Chemistry Nuclear Medicine: from Photons to Physiology
Current Pharmaceutical Design Recent Advances in Small Molecule Prodrugs for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Evolution of Ipsilateral Head and Neck Radiotherapy
Current Cancer Therapy Reviews Melanin-Concentrating Hormone Receptor 1 Antagonists: A New Perspective for the Pharmacologic Treatment of Obesity
Current Medicinal Chemistry Evolution of the Strategies for Screening and Identifying Human Tumor Antigens
Current Protein & Peptide Science New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer
Current Drug Targets Preface [ Hot Topic: Radiation Oncology as Mainstay of Modern Cancer Medicine (Guest Editors: Claus Belka & Verena Jendrossek)]
Current Medicinal Chemistry - Anti-Cancer Agents Meet Our Editorial Board Member
Current Medicinal Chemistry The Update of NGAL in Acute Kidney Injury
Current Protein & Peptide Science Drug Targeting Strategies for Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry Journey of 2′-deoxy-2′-fluoro-5-methyl-1-β-D-arabinofuranosyluracil (FMAU): from Antiviral Drug to PET Imaging Agent
Current Medicinal Chemistry Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Current Medicinal Chemistry Neurotrophins in the Lower Urinary Tract: Becoming of Age
Current Neuropharmacology Hepatic Steatosis and Peroxisomal Fatty Acid Beta-oxidation
Current Drug Metabolism Extracellular Matrix Scaffolds for Tissue Engineering and Regenerative Medicine
Current Stem Cell Research & Therapy Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Use of Recombinant Human Erythropoietin as an Antianemic and Performance Enhancing Drug
Current Pharmaceutical Biotechnology Chemical and Radiochemical Considerations in Radiolabeling with α-Emitting Radionuclides
Current Radiopharmaceuticals